1. Home
  2. GERN vs UTF Comparison

GERN vs UTF Comparison

Compare GERN & UTF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GERN
  • UTF
  • Stock Information
  • Founded
  • GERN 1990
  • UTF 2004
  • Country
  • GERN United States
  • UTF United States
  • Employees
  • GERN N/A
  • UTF N/A
  • Industry
  • GERN Biotechnology: Pharmaceutical Preparations
  • UTF Finance Companies
  • Sector
  • GERN Health Care
  • UTF Finance
  • Exchange
  • GERN Nasdaq
  • UTF Nasdaq
  • Market Cap
  • GERN 2.5B
  • UTF 2.5B
  • IPO Year
  • GERN 1996
  • UTF N/A
  • Fundamental
  • Price
  • GERN $2.92
  • UTF $24.18
  • Analyst Decision
  • GERN Strong Buy
  • UTF
  • Analyst Count
  • GERN 10
  • UTF 0
  • Target Price
  • GERN $7.15
  • UTF N/A
  • AVG Volume (30 Days)
  • GERN 14.5M
  • UTF 266.0K
  • Earning Date
  • GERN 02-26-2025
  • UTF 01-01-0001
  • Dividend Yield
  • GERN N/A
  • UTF 8.21%
  • EPS Growth
  • GERN N/A
  • UTF N/A
  • EPS
  • GERN N/A
  • UTF N/A
  • Revenue
  • GERN $29,480,000.00
  • UTF N/A
  • Revenue This Year
  • GERN $31,478.06
  • UTF N/A
  • Revenue Next Year
  • GERN $290.89
  • UTF N/A
  • P/E Ratio
  • GERN N/A
  • UTF N/A
  • Revenue Growth
  • GERN 9199.68
  • UTF N/A
  • 52 Week Low
  • GERN $1.64
  • UTF $18.15
  • 52 Week High
  • GERN $5.34
  • UTF $24.49
  • Technical
  • Relative Strength Index (RSI)
  • GERN 26.53
  • UTF 50.56
  • Support Level
  • GERN $2.80
  • UTF $23.32
  • Resistance Level
  • GERN $3.68
  • UTF $24.50
  • Average True Range (ATR)
  • GERN 0.17
  • UTF 0.30
  • MACD
  • GERN -0.04
  • UTF 0.06
  • Stochastic Oscillator
  • GERN 13.64
  • UTF 72.88

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

About UTF Cohen & Steers Infrastructure Fund Inc

Cohen & Steers Infrastructure Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is total return with an emphasis on income. It invests majority of its managed assets in securities issued by infrastructure companies, which consists of utilities, pipelines, toll roads, airports, railroads, ports, telecommunications companies, and other infrastructure companies, under normal market conditions.

Share on Social Networks: